Measles (rubeola) is a
contagious childhood disease caused by a virus and spread by coughing, sneezing or
breathing on another individual. During measles, the body literally burns up the
cells containing the invading virus. This incineration takes place at the site
of the spots or rash. Measles in young infants, teenagers and adults can be severe
with incredible complications and a high mortality rate.
The incubation period is typically 10 to 20 days
and the infection lasts several weeks. Most cases of measles are mild and symptoms begin
with a light, hacking cough, low fever, runny eyes and nose and general signs of a cold.
Four to five days before the skin breaks out into spots, the cough can become more severe
along with hacking, swelling, redness of the eyes and sensitivity to light. Fevers
can be as high as 104-105 F. No need to go into panic mode. Fever is not the
enemy. High temperatures are what helps the body kill off the infection. High
fever and cold do not respond to antibiotics, aspirin or cough medicine. Best to let
the body naturally deal with the infection the way it was created to do so.
The
symptoms increase before the rash appears and 24-49 hours before the rash appears, the
inside of the mouth is covered with grayish-white dots surrounded by reddening. In the
beginning the rash is faint and starts appearing behind the ears becoming darker as
it spreads to the face, neck and arms within 24 hours. Several days later it fades away
moving to the legs and feet and then gradually fades from the rest of the body in the next
few days. Once it all disappears, the child's immune system has "graduated" from
it's challenge and can be deemed not only more mature, but immuned for the rest of the
child's life. Recovery from measles in a previously healthy child is usually
complete without complications. Rarely, there are those that need a second
exposure before having been fully challenged and graduated into full immunity.
A severe case
of measles can include secondary infections such as otitis media (inner ear infections),
strep, bronchitis, pneumonia, hepatitis and Haemophilus influenza. Occasionally, extremely
high fevers, brain inflammation and convulsions can be followed by permanent brain damage,
transverse myelitis, subacute sclerosing panencephalitis, deafness, blindness, paralysis,
and death. Complications are more common in adults, in immune compromised or chronically
ill children and in babies under one year old.
An atypical, severe form
of measles has been seen in individuals who have been vaccinated.
This arose after the first introduction of a measles vaccine. This is
resistant to treatments and often degenerates into pneumonia or meningitis. Symptoms
begin with a fever, headache and stomach pain for several days and then a rash appears on
the hands and feet and progresses towards the head - just the opposite progression that is
seen in natural measles. The rash is especially noticeable on the legs and in body
creases. Live virus measles vaccine, which is licensed for use in the U.S. today,
can sometimes cause vaccine strain measles virus infection, which is very severe and can
end in death.
History shows that in advanced countries where
better hygiene was practiced, children recovered from measles without complications.
In 1900 there were 13.3 measles deaths per 100,000. By 1955 the death rate was 0.03
per 100,000 a decline of 97.7% eight years before the 1st vaccination.
Between 1915 and 1958 there was a decline in death from measles
in the USA and England by 95%.
It is admitted that little is known about the long
term affects after a high titre live measles vaccine. One was used in a randomized
trial in Senegal. At birth, infants were "assigned" a vaccination at five
months followed by a low titre Schwarz vaccine at 10 months of age. All were
followed for 24-39 months. The study found that the mortality after vaccination was
significantly higher in two of the three groups. Those two received the high titre
vaccines. The Senegal study did not demonstrate decrease in disease incidents.
Other studies published have stated that these
high titre vaccines contribute to the high mortality rate of the female recipients.
One of them conducted in Guinea-Bissau, Africa. Another study was conducted
in Gambia. The Gambian study was to only compare the two vaccines: Schwarz and the
Edmonston-Zagreb. The "vaccine investigators" for this trial, with the
simple stroke of the pen, decided that the two vaccines were just as "safe" and
"effective" as the other simply because they brought the same adverse reactions.
Not because neither prevented adverse reactions.
The National Health Federation put out a report in
1963 of a study conducted by the WHO. WHO's study revealed that individuals
vaccinated for measles were 14 times more likely to contract the disease than the
unvaccinated. The 20th Immunization Conference Proceedings of May 6-9, 1985 shed
light on another government study was conducted in which made note that the
"non-preventable" cases of measles occurred in the vaccinated. In the 70's
the measles death rate was the exact same as in the 60's.
Experimentation moves to California.
From 1989-1991 Pfizer conducted measles vaccine trial with Kaiser Permanente, the L.A.
County Department of Health, and the CDC (Centers for Disease Control and
Prevention). Over 700 "mostly minority" infants were injected with the
Edmonston Zagreb measles vaccine which parents were not made aware was strictly
experimental.
Lets talk some
more on Efficacy. Does the vaccine even work? A high proportion of individuals vaccinated
early in life were later found in their adult hood to having developed cervical cancer,
skin cancers and multiple sclerosis. One may look at that and say it's strictly
coincidental. However, these cases caused enough concern to be reported in the
Lancet Medical Journal in 1985.
From 1983-1990 there has been a 423% increase in
the umber of measles cases. The CDC puts out a weekly report. In their June
6th,1986 publication they note that 80% of notified cases of measles had been
vaccinated. In 1984 100% of vaccinated students developed measles. CDC had
this to say:
"This outbreak demonstrates that transmission of measles can occur within a school
population with a documented immunization level of 100%...vaccinated
persons were at greater risk of clinical illness if they had close
exposure to a measles patient." Antibody titres were detected for those with
resent booster vaccinations. However, no long term
study with scientific analysis exists that definitively concludes this
directly correlates with protections from the disease. CDC further states that
"this outbreak suggests that measles transmission can occur within the 2%-10% of expected vaccine failures." In the same
year Corpus Christi, TX experienced an epidemic in which it is noted that 99% of the
children affected had been vaccinated. 95% of them were presumed to be immune.
This according to the New England Journal of Medicine. In 1992 Dr. Atkinson of the
CDC reported at the Drug Administration Workshop that "Measles transmission has been
clearly documented among vaccinated persons". He went on to admit that in some
of the large outbreaks, 95% of the cases had been vaccinated. Between 1986-1994
1,762 "batches" of the measles vaccine were released for mass vaccination in
India. During
the campaign 79 children died within twenty-four hours. Currently, India is testing
a new nasal measles vaccine.
There is a
myth that mothers vaccinated during childhood for measles pass on maternal antibodies to
their children. Yet these mothers, never having acquired the disease naturally, do
not have the natural measles antibodies to pass onto their children. Therefore, babies
born today are left vulnerable to the disease from the moment of birth. By 1993 more
than 25% of measles cases were occurring in babies under the age of one. In an
Albuquerque, NM Journal the CDC attributed this to the growing number of mothers who were
vaccinated during the 1960's, 70's and 80's. The observation over three decades is
clearly made by the U.S. government that the MMR denies the human body of natural immunity
to be passed down.
June 2006 one infant died and five others were hospitalized in critical
condition in Ho Chi Minh City of Vietnam. Head of the National Open Vaccination
Program, Do Sy Hien, said that the number of children receiving compulsory vaccinations
dropped due to the incidents. He admitted that Priorix, the MMR injection
involved should not have been on the program. Great Britain also experienced deaths after
the jab at the same time. Although, this is a not a first for any country.
Encephalopathy is a brain
disorder often followed by measles vaccination. In one particular study published in
1998, medical records of children were obtained who had received their first does between
1970-1993. Criteria was met by the identification of encaphalopathy within 15 days
of inoculation. 48 children of 10-49 months met this criteria. They had either
received the measles alone or in the triple combination vaccine. Eight children died. The rest suffered mental regression,
retardation, chronic seizures, motor and sensory deficits, and movement disorders.
Subacute
Sclerosing Panencephalitis is another side effect listed after measles vaccination.
An infection of the central nervous system. Progression in this adverse
reaction leads to death of the nerve cells and brain inflammation.
Mumps
can cause fever, headache and inflammation of the salivary glands, which causes the
swelling of the cheeks. Incubation is generally 14 to 21 days. Beginning symptoms may be
low fever, headache, vomiting and earache. Swelling first appears in front of the ear
above the jaw line and sometimes involves the glands under the chin. There is discomfort
when eating because the saliva irritates swollen glands. One side or both sides of the
face may swell. Swelling usually goes away in a week and recovery is usually complete
without complications.
In rare occasions mumps can be
severe and cause an inflammation of the lining of the brain and spinal cord. This is
meningitis. Symptoms include severe headache, vomiting, irritability,
lethargy. Sometimes it can cause inflammation of the brain itself and can cause
permanent brain damage, deafness or death. Adolescent or adult males who get mumps
can develop painful inflammation and swelling of the testicles (orchitis). Rarely,
this causes sterility. Life long immunity and a more mature immune system is also
the result of recovery from this challenging disease.
Though several vaccine
strains exist, the most popular mumps vaccine is derived from the Jeryl Lynn strain of the
mumps virus. The Jeryl Lynn strain is an attenuated form of the mumps virus, produced by
passage in embryonated hensí eggs and chick embryo cell cultures.
There are many published
adverse reactions to mumps vaccination. Ranging from atypical mumps, which is a
severe form of the disease after vaccination, to meningitis, diabetes, and causing
higher rates of mumps cases. The Lancet reported that in West Germany, authorities
had listed twenty-seven neurological reactions to the mumps vaccine including Meningitis,
febrile convulsions, and epilepsy. There are 30,000 new cases of epilepsy. 10,000 of which
are children, in the UK alone.
Rubella
is also known as German Measles or the "three day measles" and is usually
a mild childhood disease which used to be common in American children five to nine years
old. However, today in the U.S., rubella is most frequently seen among teenagers and young
adults. In these age brackets it can be severely serious.
In 1969, there
were 57,686 cases of rubella reported in the U.S., the highest number of cases reported In
one year. In 1992, there were 160 cases of rubella reported in the U.S. with one death
reported to have resulted from disease complications. In 2002, there were only 18 reported
cases.
The virus can be found in the throat and blood of
an infected individual. Incubation period is 14 to 21 days.
Symptoms begin with a mild cold, low-grade fever and swelling of the glands in the back of
the neck and under the chin. Sometimes the glands behind the ears become enlarged. A pink
rash first appears on the face and then spreads to the arms, head, chest and sometimes the
legs. Young adults, especially young women, who get rubella may have swollen glands
in the back of the neck and some pain, swelling and stiffness in the joints (arthritis)
that persists for several weeks. Recovery from rubella is usually quick but occasionally
brain inflammation and chronic arthritis can cause permanent damage.
If a woman
gets rubella in the first trimester of pregnancy, she has a 20 to 25 percent greater
chance of giving birth to a deformed baby and is at risk of suffering a miscarriage. Birth
defects can include blindness, damage to the heart and major arteries, deafness,
abnormally small brain and mental retardation.
Three rubella vaccines
were licensed in the U.S. in 1969: HPV- 77:DE-5 (duck embryo), HPV-77:DK-12 (dog kidney),
and Cendehill (rabbit kidney) strains. The HPV-77:DK-12 was later removed from the market
because there was a higher rate of joint complaints following vaccination with this
strain. In January 1979, the RA 27/3 (human diploid fibroblast) strain (Meruvax-II) was
licensed and all other strains were discontinued. The RA 27/3 rubella vaccine is a live
attenuated virus. It was first isolated in 1965 at the Wistar Institute from a
rubella-infected aborted fetus. The virus was attenuated by 25-30 passages in tissue
culture, using human diploid fibroblasts. It does not contain duck, chicken or egg
protein. The method in which the unborn child was found infected with Rubella for vaccine
manufacturing was conducted with brutal deception and intended heartless murder of the
child. The mother had no prior knowledge of what was to become of her baby once the
physician convinced her to "terminate" the pregnancy. Learn the details here.
Conflict of Interests?
Dr. Samuel Katz was the Wilburt Cornell Davison Professor and Chairman Emeritus of
Pediatrics at Duke University. He has Chaired the Committee on Infectious Diseases
of the American Academy of Pediatrics (the Redbook Committee), the Advisory Committee on
Immunization Practices (ACIP) of the CDC, the Vaccine Priorities Study of the Institute of
Medicine (IOM), and several WHO and CVI vaccine and HIV panels. He is a member of
many scientific advisory committees and boards including the NIH, IOM, WHO, St. Jude
Children's Research Hospital, The Burroughs Wellcome Fund (Chairman), and the Hasbro
Children's Foundation. He was Chairman of the Public Policy Council of the
Infectious Diseases Society of America (IDSA) and currently co-chairs IDSA's Vaccine
Initiative. Having relinquished the Chairmanship in 1990, his principle activities
now are with vaccines and pediatric AIDS. He participates in the clinical research trials
of the NIH, served on their Committee for AIDS Vaccines, devotes time each week to the
care of children with HIV infection, and was a member of The Pediatric Executive Committee
of NIAID's ACTG. His vaccine policy work continues through CDC, IOM, NIH, IDSA and WHO
committees and consultancies.
John Enders |
Dr. Sam Katz, with the help of Dr. John Enders
developed a measles vaccine. In a chapter from his book “Vaccines”,
he writes with two others; “The risk of serious complications and death is
increased in infants and adults.” And later, “The highest risk of death
was in children younger than one year and adults. Neither
vaccination nor revaccination is a guarantee that one will be protected from the measles
and could well be a significant problem in the future. Boosting
of antibody titers appears to be transient, with several investigators finding antibody
levels to the pre-revaccination level within months to years.”
At the Oklahoma State University's Center for
Health Sciences in Tulsa, clinical trials of a new measles vaccine are being
conducted. Doctor Stanley Grogg says the trials are in the third phase of a
four-phase national study to find a new measles vaccine. He says the pharmaceutical
company that makes the vaccine used a 1967 measles virus to make the original vaccine and
that vaccine will be used up in two to three years, so a new vaccination must be found.
Here is the original article. OSU-Tulsa Selected To Hold Trials For New Measles Vaccine
